Gain Therapeutics

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.

Presentation Details

Date: September 28, 2023

Time: 12:40 p.m. ET

Format: Fireside Chat

Please contact your Cantor Fitzgerald representative for more information.

A webcast of the presentation can be accessed through the Events section of the Company’s website at /investors-media/overview.html. An archived replay of the webcast will be available on the Company’s website following the conference.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, has been approved for clinical testing in Australia.

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, please visit  and follow us on .

Investor & Media Contact:

Susan Sharpe

Linnden Communications

(919) 602-2330



EN
25/09/2023

Underlying

Gain Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gain Therapeutics

 PRESS RELEASE
Free
Gain Therapeuti...

Gain Therapeutics Reports Financial Results for Second Quarter 2025 an...

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds BETHESDA, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: ...

August 12, 2025 1 EN
 PRESS RELEASE
Free
Gain Therapeuti...

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conf...

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29th through Wednesday, July 30th. Fireside Presentation Details Date: We...

July 24, 2025 1 EN
 PRESS RELEASE
Free
Gain Therapeuti...

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock and warrants to purchase up to an aggregate of 2,250,820 shares of its common stock. The public offering price for each set of two shares of common stock and accompanyi...

July 16, 2025 1 EN
 PRESS RELEASE
Free
Gain Therapeuti...

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Proposed Public Offering BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option...

July 15, 2025 1 EN
 PRESS RELEASE
Free
Gain Therapeuti...

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1...

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now expected to also track earlier; available in 4Q 2025 instead of 1Q 2026 Gain will continue screening patients for enrollment through July 31st, 2025, at the request o...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch